268 related articles for article (PubMed ID: 11888344)
1. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
4. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
5. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
6. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Nordberg A; Darreh-Shori T; Peskind E; Soininen H; Mousavi M; Eagle G; Lane R
Curr Alzheimer Res; 2009 Feb; 6(1):4-14. PubMed ID: 19199870
[TBL] [Abstract][Full Text] [Related]
7. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
8. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
9. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
10. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
Kuhl DE; Koeppe RA; Snyder SE; Minoshima S; Frey KA; Kilbourn MR
Ann Neurol; 2006 Jan; 59(1):13-20. PubMed ID: 16278840
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
12. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
13. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Rakonczay Z
Acta Biol Hung; 2003; 54(2):183-9. PubMed ID: 14535624
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Ballard CG
Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH
J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481
[TBL] [Abstract][Full Text] [Related]
17. Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.
Wright CI; Geula C; Mesulam MM
Ann Neurol; 1993 Sep; 34(3):373-84. PubMed ID: 8363355
[TBL] [Abstract][Full Text] [Related]
18. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA; Al-Jafari AA; Yu QS; Greig NH
Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity.
Darvesh S; MacDonald SE; Losier AM; Martin E; Hopkins DA; Armour JA
J Auton Nerv Syst; 1998 Jul; 71(2-3):75-84. PubMed ID: 9760044
[TBL] [Abstract][Full Text] [Related]
20. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
Darreh-Shori T; Soininen H
Curr Alzheimer Res; 2010 Feb; 7(1):67-73. PubMed ID: 20205672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]